Aignostics develops AI foundation models for precision medicine, specializing in processing complex biomedical and digital pathology data. The company offers products for tumor microenvironment profiling and services for target discovery and translational research. Their platform enables the development of validated digital diagnostic tools to improve drug development and patient outcomes.
Funding
$54.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional pathology analysis relies on manual review of tissue samples, which is time-consuming, subjective, and can miss subtle but critical disease indicators. Analyzing complex imaging and omics data to identify novel drug targets and improve clinical research is challenging due to the scale and complexity of the data.
Solution
Aignostics offers an AI-powered platform that enhances precision diagnostics in pathology by analyzing complex imaging and omics data. Their foundation model, trained using a pathologist-in-the-loop approach, achieves high accuracy on histopathology benchmarks while requiring significantly less training data. The platform identifies novel drug targets, streamlines translational research, and develops regulatory-grade algorithms for clinical trials and companion diagnostics. Aignostics' technology combines explainable AI, proprietary multimodal pathology data, and scientific expertise to improve patient outcomes and accelerate drug development.
Target Audience
Aignostics targets biopharmaceutical companies, clinical research organizations, and healthcare providers seeking to improve drug development, clinical trials, and precision diagnostics through advanced AI-powered pathology analysis.
Features
- Industry-leading foundation model for histopathology with over 90% accuracy on key benchmarks
- Patented, explainable AI technologies that reduce time to model and improve performance
- Proprietary access to high-quality, multimodal pathology data across standard of care modalities (histopathology, omics, clinical outcomes)
- GCP-ready clinical trial platform developed under ISO 13485 certified QMS and ISO/IEC 27001 certified ISMS
- Anomaly detection and generalizability capabilities for diverse pathology tasks
- Target identification module for novel target discovery in biopharma
- Translational research module for analyzing complex imaging and omics data
- Regulatory-grade algorithm development for clinical trials and companion diagnostics